Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Echinobase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
Echinobase
ECB-ART-50092
J Vasc Interv Radiol 2013 Aug 01;248:1083-92; quiz 1093. doi: 10.1016/j.jvir.2013.04.019.
Show Gene links Show Anatomy links

Personalized oncology in interventional radiology.

Abi-Jaoudeh N , Duffy AG , Greten TF , Kohn EC , Clark TW , Wood BJ .


Abstract
As personalized medicine becomes more applicable to oncologic practice, image-guided biopsies will be integral for enabling predictive and pharmacodynamic molecular pathology. Interventional radiology has a key role in defining patient-specific management. Advances in diagnostic techniques, genomics, and proteomics enable a window into subcellular mechanisms driving hyperproliferation, metastatic capabilities, and tumor angiogenesis. A new era of personalized medicine has evolved whereby clinical decisions are adjusted according to a patient's molecular profile. Several mutations and key markers already have been introduced into standard oncologic practice. A broader understanding of personalized oncology will help interventionalists play a greater role in therapy selection and discovery.

PubMed ID: 23885909
PMC ID: PMC3742380
Article link: J Vasc Interv Radiol
Grant support: [+]


References [+] :
Adams, Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. 2011, Pubmed